{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:57:10Z","timestamp":1778770630524,"version":"3.51.4"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded <jats:italic>in vitro<\/jats:italic>, and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1524842","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:15:22Z","timestamp":1747631722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Gang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20240119-00035","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1646721","article-title":"Pembrolizumab for the treatment of cervical cancer","volume":"19","author":"Marret","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.01.015","article-title":"Unleash the power of the mighty T cells-basis of adoptive cellular therapy","volume":"136","author":"Sukari","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/d41573-024-00035-1","article-title":"FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discovery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1501","article-title":"The precision prevention and therapy of HPV-related cervical cancer: New concepts and clinical implications","volume":"7","author":"Hu","year":"2018","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.07.044","article-title":"HPV-16 E5 down-regulates expression of surface hla class i and reduces recognition by CD8 T cells","volume":"407","author":"Campo","year":"2010","journal-title":"Virology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20558","article-title":"E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I","volume":"113","author":"Ashrafi","year":"2005","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0042-6822(03)00103-x","article-title":"The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma","volume":"310","author":"Zhang","year":"2003","journal-title":"Virology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01053-10","article-title":"Cd1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (Hpv) E5 protein: A possible mechanism for immune evasion by hpv","volume":"84","author":"Miura","year":"2010","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.629350","article-title":"CXCL10 produced by HPV-positive cervical cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55070384","article-title":"Key molecular events in cervical cancer development","volume":"55","author":"Balasubramaniam","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155592","article-title":"Evidence that the viral oncoproteins E6 and E7 of HPV induce the expression of a functional il-2r on cervical cancer cells","volume":"148","author":"Trujillo-Cirilo","year":"2021","journal-title":"Cytokine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.jid.2019.03.1162","article-title":"HPV16 E7-driven epithelial hyperplasia promotes impaired antigen presentation and regulatory T-cell development","volume":"139","author":"Bashaw","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23162","article-title":"Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element","volume":"122","author":"Piersma","year":"2008","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.106","article-title":"Variation of tumor-infiltrating lymphocytes in human cancers: Controversy on clinical significance","volume":"3","author":"Sasada","year":"2011","journal-title":"Immunotherapy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600651103","article-title":"Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses","volume":"103","author":"Wiedemann","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8(+) T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2972","article-title":"Predominant TH2\/TC2 polarity of tumor-infiltrating lymphocytes in human cervical cancer","volume":"167","author":"Sheu","year":"2001","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00521-2","article-title":"Cd4(+) T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In vivo CD4(+) T cell differentiation and function: Revisiting the Th1\/Th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12905-020-00972-0","article-title":"The disease stage-associated imbalance of Th1\/Th2 and Th17\/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Womens Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0806-7","article-title":"Metabolic heterogeneity underlies reciprocal fates of T(H)17 cell stemness and plasticity","volume":"565","author":"Karmaus","year":"2019","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic cell regulation of t helper cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.11.004","article-title":"Treg cells in different forms of uterine cancer","volume":"415","author":"Hou","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x","article-title":"Cd4(+) T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci126397","article-title":"B cell maturation antigen-specific car T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic hpv-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3826","article-title":"Adenocarcinoma of the uterine cervix shows impaired recruitment of CDC1 and CD8(+) T cells and elevated \u03b2-catenin activation compared with squamous cell carcinoma","volume":"26","author":"Rotman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104846","article-title":"Single-nucleus rna sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma","volume":"97","author":"Lin","year":"2023","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e28857","DOI":"10.1002\/jmv.28857","article-title":"Diverse intratumoral heterogeneity and immune microenvironment of two hpv-related cervical cancer types revealed by single-cell rna sequencing","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.966291","article-title":"Integrated single-cell transcriptome analysis of the tumor ecosystems underlying cervical cancer metastasis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e110757","DOI":"10.15252\/embj.2022110757","article-title":"Single-cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment","volume":"42","author":"Cao","year":"2023","journal-title":"EMBO J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.03.003","article-title":"The dynamic alternation of local and systemic tumor immune microenvironment during concurrent chemoradiotherapy of cervical cancer: A prospective clinical trial","volume":"110","author":"Li","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01123-w","article-title":"Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer","volume":"124","author":"Zhang","year":"2021","journal-title":"Br J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2060019","article-title":"Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer","volume":"18","author":"Zhu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003887","article-title":"Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen","volume":"10","author":"Guo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557006","article-title":"Anti-CD137 agonist antibody\u2013independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.138.3.989","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma","volume":"138","author":"Muul","year":"1987","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"Cd8+ T cell immunity against a Tumor\/Self-antigen is augmented by CD4+ t helper cells and hindered by naturally occurring t regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0792-6","article-title":"Dendritic cell recovery post-lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination","volume":"59","author":"Salem","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-Resistant metastatic lung cancer: A phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052676899","article-title":"Enhanced signaling through the il-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death","volume":"99","author":"Cheng","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.492","article-title":"492 phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers","volume":"9","author":"O\u2019Malley","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase ii clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11857","article-title":"Better clinical efficiency of TILs for malignant pleural effusion and ascites than cisplatin through intrapleural and intraperitoneal infusion","volume":"37","author":"Chu","year":"2017","journal-title":"Anticancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1023\/a:1006293606710","article-title":"Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas","volume":"45","author":"Quattrocchi","year":"1999","journal-title":"J Neurooncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.156.2.385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using t-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/jci157726","article-title":"Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer","volume":"132","author":"Huang","year":"2022","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2549","article-title":"A first-in-Human study of CRISPR\/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors","volume":"42","author":"Guo","year":"2024","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2551","article-title":"Harnessing the power of tumor-infiltrating lymphocytes: A first-in-Human study of GT201 as monotherapy in advanced solid tumors","volume":"41","author":"Liu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-5581","article-title":"Abstract 5581: A genetically modified tumor-infiltrating lymphocytes product (Gt202) exhibits enhanced persistence and anti-tumor efficacy against solid tumor in vivo","volume":"82","author":"Sun","year":"2022","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-2746","article-title":"Abstract 2746: Preclinical activity and manufacturing feasibility of genetically modified pdcd-1 knockout (Ko) tumor-infiltrating lymphocyte (TIL) cell therapy","volume":"82","author":"Natarajan","year":"2022","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003750","article-title":"Crispr-mediated Tgfbr2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to tgf-\u03b2 signaling","volume":"10","author":"Fix","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.172","article-title":"172 overcoming immunosuppressive tgf-Csignaling in human ovarian cancer-derived tumor infiltrating lymphocytes Via non-viral crispr engineering","volume":"9","author":"Fix","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2024-29","article-title":"Abstract 29: A genetically modified tumor-infiltrating lymphocytes product (Gt216) enhanced anti-tumor efficacy against solid tumor by fine-tuning multiple negative immune regulators","author":"Sun","year":"","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.593848","article-title":"Synthetic TILs: Engineered tumor-infiltrating lymphocytes with improved therapeutic potential","volume":"10","author":"Jim\u00e9nez-Reinoso","year":"2020","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2392897","article-title":"Cd4(+) tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts","volume":"13","author":"Jim\u00e9nez-Reinoso","year":"2024","journal-title":"Oncoimmunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3593-3_13","article-title":"Genetic modification of tumor-infiltrating lymphocytes, peripheral T cells, and t-cell model cell lines","volume":"2748","author":"Weinstein-Marom","year":"2024","journal-title":"Methods Mol Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1949896","article-title":"A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate hpv-associated tumors in a preclinical model","volume":"10","author":"Ramos da Silva","year":"2021","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6097","article-title":"Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma","volume":"39","author":"Aoto","year":"2018","journal-title":"Oncol Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29060342","article-title":"Prognostic and predictive relevance of tumor-infiltrating lymphocytes in squamous cell head-neck cancer patients treated with radical Radiotherapy\/Chemo-radiotherapy","volume":"29","author":"Koukourakis","year":"2022","journal-title":"Curr Oncol"},{"key":"B77","article-title":"Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki","year":"1991","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances mhc class i expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e28217","DOI":"10.1371\/journal.pone.0028217","article-title":"\u0393-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo","volume":"6","author":"Sharma","year":"2011","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced Cxcl16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1667\/rr1860.1","article-title":"Up-regulation of the pro-inflammatory chemokine Cxcl16 is a common response of tumor cells to ionizing radiation","volume":"173","author":"Matsumura","year":"2010","journal-title":"Radiat Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/jci69219","article-title":"Radiation and immunotherapy: A synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e27403","DOI":"10.4161\/onci.27403","article-title":"Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer","volume":"3","author":"Balermpas","year":"2014","journal-title":"Oncoimmunology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-6-49","article-title":"Density of CD4(+) and CD8(+) t lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (Crt) for rectal cancer","volume":"6","author":"Yasuda","year":"2011","journal-title":"Radiat Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550","article-title":"The Pd1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of pd-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2022.04.003","article-title":"Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy","volume":"370","author":"Diaz-Cano","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: Current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12101","article-title":"Increased expression of programmed death (Pd)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia","volume":"139","author":"Yang","year":"2013","journal-title":"Immunology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through ctl dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8345235","article-title":"TILs and anti-Pd1 therapy: An alternative combination therapy for Pdl1 negative metastatic cervical cancer","volume":"2020","author":"Yin","year":"2020","journal-title":"J Immunol Res"},{"key":"B92","article-title":"Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro","volume":"32","author":"Morisaki","year":"2012","journal-title":"Anticancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in cancers: A systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.05.009","article-title":"Regulatory T cells in cancer: An overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation","volume":"74","author":"Sahin","year":"2013","journal-title":"Hum Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-481788","article-title":"Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by Foxp3 in human regulatory T cells","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S217767","article-title":"DNA methyltransferase inhibitors: Catalysts for antitumour immune responses","volume":"12","author":"Dan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1776-3","article-title":"Improving cancer immunotherapy with DNA methyltransferase inhibitors","volume":"65","author":"Saleh","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0111","article-title":"Enhancing tumor T cell infiltration to enable cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01746-8","article-title":"Targeting JMJD1C to selectively disrupt tumor T(Reg) cell fitness enhances antitumor immunity","volume":"25","author":"Long","year":"2024","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-2653","article-title":"Phase i trial of M7824 (Msb0011359c), a bifunctional fusion protein targeting PD-L1 and tgf\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting tgf-\u03b2 and PD-L1, in second-line treatment of patients with nsclc: Results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2503","article-title":"Phase 1 study of shr-1701, a bifunctional fusion protein targeting PD-L1 and tgf-\u03b2, in patients with advanced solid tumors","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c03518","article-title":"In situ tumor-infiltrating lymphocyte therapy by local delivery of an mrna encoding membrane-anchored anti-CD3 single-chain variable fragment","volume":"18","author":"Yoon","year":"2024","journal-title":"ACS Nano"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2020.21.3.831","article-title":"Fas ligand (Fasl) in association with tumor-infiltrating lymphocytes (TILs) in early stage cervical cancer","volume":"21","author":"Anggraeni","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153849","article-title":"Tumor immune microenvironment in gynecologic cancers","volume":"15","author":"Margul","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1038\/s41598-022-11415-1","article-title":"Erbb3 methylation and immune infiltration in tumor microenvironment of cervical cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2607","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types","volume":"39","author":"Shen","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-024-01281-z","article-title":"Mrna-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors","volume":"16","author":"Trivedi","year":"2024","journal-title":"Genome Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015469","article-title":"A therapeutic DNA vaccine targeting Hpv16 E7 in combination with anti-Pd-1\/PD-L1 enhanced tumor regression and cytotoxic immune responses","volume":"24","author":"Han","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02699-0","article-title":"Recent advances in immunotherapy for cervical cancer","volume":"30","author":"Ogasawara","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-5633","article-title":"Abstract 5633: Analysis of the immune microenvironment and tumor-infiltrating immune cells across different solid tumors by combined spatial transcriptomics and proteomics","volume":"83","author":"Femel","year":"2023","journal-title":"Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of cbl-b inhibits CD8(+) t-cell exhaustion and promotes car t-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor t-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-024-02020-y","article-title":"Integrative analysis of ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy","volume":"23","author":"He","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B117","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12967-024-06036-3","article-title":"Modulating tumor-associated macrophages through Csf1r inhibition: A potential therapeutic strategy for hnscc","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e2200204","DOI":"10.1002\/bies.202200204","article-title":"Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment","volume":"45","author":"Lee","year":"2023","journal-title":"Bioessays"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-1297","article-title":"Cd8+ enriched \"Young\" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-Treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"A Preliminary Rep N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2023.0178","article-title":"An updated review of interleukin-2 therapy in cancer and autoimmune diseases","volume":"44","author":"Radi","year":"2024","journal-title":"J Interferon Cytokine Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/01.Cji.0000016820.36510.89","article-title":"A phase i study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific t lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J Immunother"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/s41467-021-22980-w","article-title":"A cytokine receptor-masked Il2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy","volume":"12","author":"Hsu","year":"2021","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer-current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the car T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-0236","article-title":"Expansion of tumor-infiltrating CD8(+) T cells expressing pd-1 improves the efficacy of adoptive t-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41591-021-01248-2","article-title":"Author correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"27","author":"Fraietta","year":"2021","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2680","article-title":"Isolation of t-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression","volume":"23","author":"Parkhurst","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.08.014","article-title":"Artificial T cell adaptor molecule-transduced TCR-T cells demonstrated improved proliferation only when transduced in a higher intensity","volume":"18","author":"Sakai","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121257","article-title":"Nanoparticle delivery of recombinant il-2 (Ballkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy","volume":"280","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"key":"B140","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12916-024-03420-0","article-title":"Il-2-Free tumor-infiltrating lymphocyte therapy with pd-1 blockade demonstrates potent efficacy in advanced gynecologic cancer","volume":"22","author":"Guo","year":"2024","journal-title":"BMC Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:15:24Z","timestamp":1747631724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2025.1524842"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1524842","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"1524842"}}